D. Boral Capital Reiterates Buy Rating for UroGen Pharma (NASDAQ:URGN)
UroGen Pharma (NASDAQ:URGN – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They currently have a $25.00 price target on the stock. D. Boral Capital’s price objective suggests a potential upside of 131.05% from the stock’s current price. UroGen […]
More Stories
Landman Season 3: News and Updates on Release Date and Trailer
Landman has gained popularity from its very first season. The season premiered on November 17, 2024, and continued for approximately...
A Dawn of Harmony: Envisioning True Peace Between the United States and Iran
By Stephen Zogopoulos, USNN World News January 17, 2026 – In the shadow of escalating protests across Iran and the...
Judge Restricts ICE Actions Against Protesters in Minnesota
By Kimberly Hayek A federal judge in Minnesota on Friday ruled that federal immigration agents can’t detain or use nonlethal...
Over Half of New Hires Land Jobs in a Month—With Tempered Expectations
By Panos Mourdoukoutas The labor market is becoming more efficient and flexible, with job seekers finding and accepting positions more...
Volodymyr Zelenskyy’s Net Worth: Assets, Salary, and Real Estate
Zelenskyy’s remark on the current situation of the abduction of Venezuela’s President and his wife has brought him to the...
Walz Responds to Reports of Federal Probe for Allegedly Obstructing Law Enforcement
By Jill McLaughlin Gov. Tim Walz called reports of a federal investigation into his recent public statements encouraging Minnesotans to...